





PRIVATE PRACTICE - THE
CHOLESTEROL MONITOR
K Steyn, J M Fourie, J Shepherd
Background. 1bis paper reports data on the detection and
management of hypercholesterolaemia in patients attending
general practitioners in private practice in South Africa.
Methods. The frequency of cholesterol testing and the level at
which active therapeutic intervention occurred at medical
practices were monitored over a 2-year period. A sample of
200 medical practitioners was selected from private practices
in major citie;. Data on patients seen by the selected doctors
during a 5-day monitoring period were recorded on a
standardised form.
Results. 12842 patients were seen by the 200 private practice·
GPs. More men (18.7%) than women (10.4%) had coronary
heart disease (CHD), and their mean total cholesterol (TC)
levels were 5.9 mmol/l and 6.0 mmol/l, respectively. Only
3.1% of the patients were reported to have familial
hypercholesterolaemia (FH) and 12.8% were reported to have
a family history of CHD. Reported smoking rates were
exceptionally high (77.5% of women and 64.4% of men). The
most commonly prescribed group of lipid-lowering agents
was HMG-CoA reductase inhibitors.
Conclusions. Inadequate management of hypercholesterol-·
aemia leaves many patients with a high risk of CHD
mortality in South Africa. Appropriately investigated patients
with hypercholesterolaemia should receive treatment to
reduce cardiovascular disease using more effective TC control
programmes than are currently used in South Africa.
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The management of hypercholesterolaemia, as one of the major
risk factors for ischaemic heart disease (IHD) and other
atherosclerosis-related cardiovascular diseases, has been
addressed via consensus management guidelines in many
countries during the past decadel-l This became necessary as
population surveys in several countries with typical
westernised lifestyles showed that hypercholesterolaemia is
poorly diagnosed and frequently managed ineffectively. In
South Africa several community-based studies, which included
serum total cholesterol (TC) measurements,' suggested that
lipid disorders were underdiagnosed. From these localised,
cross-sectional surveys, it was crudely estimated that there.are
5 million adults who have TC levels that put them at risk of
developing IHD. These findings resulted in the Heart
Foundation of Southern Africa calling for the formulation of
guidelines to manage hypercholesterolaemia, and consequently
the publication of the action limits for serum TC in 1988'
Selective screening was recommended, targeting individuals
likely to have elevated TC levels or who might be at high risk
for IHD on the basis of a family history of early IHD or other
IHD risk factors.
After the publication of the Heart Foundation's action limits,
an extensive cholesterol education programme incorporating
information from the guidelines was targeted at general
practitioners. Patients were also targeted by means of
brochures in doctors' waiting rooms; these enabled patients to
identify whether they were at risk of IHD, and if so to request
TC measurement. The current survey was conducted 7 - 8 years
after these measures were introduced.
The actual burden of hypercholesterolaemia and the
strategies explored by private practitioners to address it have
not yet been evaluated in South Africa. Although a national
survey has been planned to determine the burden of adult
disease in this country, mass screening of serum TC levels has
not been considered due to logistic factors and costs.
In various European countries regular surveys conducted
among private practitioners have reported trends in the
management of hypercholesterolaemic patients since 1988.
These surveys were conducted by independent professional
market research organisations and sponsored by the
phan:laceutical company Merck, Sharp & Dohme (MSD)
among approximately 406 000 patients who attended randomly
selected private practitioners. These data, available from MSD
as a software package, are referred to as the Cholesterol
Monitor. TIle data were analysed at Glasgow University.'
A similar study financed by MSD was conducted in South
Africa. Data collection was done by the company Strategic
Marketing Services. The objective of the study was to monitor
the frequency of cholesterol testing and the level at which there
is active therapeutic intervention by medical practitioners over
a 2-year period. This paper reports the findings of the South
African Cholesterol Monitor conducted in 1993 and 1994. Data
analyses were conducted at the Medical Research Council in
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collaboration with Glasgow University. Particular focus was
placed on the reported lifestyle modifications that occurred
among patients who were found by the participating clinicians
to be suffering from coronary heart disease (CHD) as well as
familial hypercholesterolaemia (FH). The South African data
will also be compared with those for certain European
countries.
METHODS
Sample of private practitioners
The sampling frame routinely used by the market research
company is based on the list of GPs and specialists registered
with the South African Medical and Dental Council. The
company updates this list at regular intervals and identifies the
number of patients usually seen by each doctor. A random
sample of 800 (400 per year) medical practitioners in private
practice was selected countrywide from the company's list in
1993 and 1994. The aim was to select approximately 70 general
practitioners and 30 specialists catering for cardiology patients
each year. These specialists were registered cardiologists or
physicians who reported seeing at least 25% of their patients
for cardiological conditions. One doctor was randomly selected
from each practice where there was more than one partner and
no doctor participated in the study period twice. The sample
was stratified according to geographical area using
metropolitan and non-metropolitan categories. Only doctors
who saw on average a minimum of 25 patients per day were
considered. In 1993 and 1994 the list of 400 medical
practitioners was supplied to the fieldworkers in each area who
had to see the specified number of doctors as set out in Table 1.
Data collection
The fieldwork procedure was piloted at five practices to ensure
the feasibility of the process. Data were recorded for all
patients over the age of 25 years seen by the selected doctors
during a 5-day monitoring period during December of each
year. The data were captured by the doctor on a standardised
form at the time of consultation, similar to the one used in the
European surveys. The 5-day survey period for the
participating doctors took place during consecutive working
weekdays and respondents started monitoring on different
days of the week to ensure an overall uniform method of
reporting for every day of the week.
The standardised form contained information as to whether
the patient was obese, a smoker or suffering from any other
conditions that put the patient at risk of IHD. It also recorded
whether serum cholesterol levels had been determined. In
addition, the lipid levels were recorded for patients who
received either a cholesterol-lowering diet or medication. The
participating private practitioners were remunerated at the rate
of a consultation fee. The doctors received specific briefing
regarding the required procedures, and the trained
fieldworkers checked each doctor's records after the first few
cases to ensure correct completion of the special forms. These
were collected by the fieldworkers and were computerised and
analysed centrally in the USA, as were all the surveys done
globally. (The questionnaire is available on request from the
authors.)
RESULTS
The sampling procedures selected 200 doctors from a random
Table I. Distribution of the sampling frame of 800 practices and the realised sample of 200 private practices participating in the Cholesterol
Monilor survey
1993 and 1994 sample
Random Total number General on-
sample frame selected practitioner Specialist Metropolitan metropolitan
Total 800 200 140 60 160 40
Metropolitan areas 640 160 100 60 160
Pretoria, Witwatersrand and Vereeniging 344 86 56 30 86
Cape Town 138 34 20 14 34
Durban 74 20 13 7 20
Pietermaritzburg 34 2 1 1 2
East London/Port Elizabeth 14 9 6 3 9
Bloemfontein 36 9 4 5 9
on-metropolitan areas 160 40 40 40
I!li
Southern Transvaal (around' Johannesburg) 46 12 12 12
orthem Transvaal (around Pretoria) 22 6 6 6
atal (around Durban) 46 12 12 12
Orange Free State (around Bloemfontein) 20 4 4 4
Western Cape (around Cape Town) 18 4 4 4
Eastern Cape (around Port Elizabeth) 8 2 2 2
~Around' a city means small towns dose to the metropolitan areas, e.g. in the Western Cape one GP from Stellenbosch and one from Paarl were selected from the provided random
sample frame.
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sample of 400 practices per year for 1993 and 1994. The
distribution of these and the realised sample of practices are
shown in Table 1. During these two survey periods 12 842
patients were seen by the 200 GPs in private practice.
Table II shows the profile of the South African patients
whose records were used for the local Cholesterol Monitor.
Overall, GPs reported that 39.1% of the participating patients
had had TC levels measured at some stage, and more than 85%
of the 39% had their latest TC level recorded. Almost 50% of
the participating men and only about 30% of the women had
these data recorded. Data for those with recorded TC levels
showed that almost 25% had TC levels above 6.5 rnrnol/l. For
patients who were reported to suffer from CHD, 68.3% of men
and only 49.5% of women had recorded TC levels. More men
than women had CHD and their mean TC levels were
5.9 rnrno1/1 and 6.0 rnrno1/l, respectively. Only 3.1% of the
patients were reported to have FH and 12.8% were reported to
have a family history of CHD.
CHD risk factors were exceedingly common in the total
group of patients, with 81% having at least one of the following
risk factors: hypertension, diabetes, cigarette smoking, family
history of CHD, and/or raised serum triglyceride levels.
Particularly high smoking rates were reported by the
participating doctors for the total group (77.5% for women
and 64.4% for men).
Table III provides the TC profile and treatment pattern of
patients who were reported to have FH and those reported to
have suffered and not suffered from CHD. All the FH patients'
doctors reported that their TC levels had been measured in the
past. These FH patients had the most recorded TC levels, while
almost 90% of the CHD patients and 85% of those without
CHD had recorded TC levels. The FH patients had a higher TC
level than the other two groups whose TC levels were very
similar. A mere 5.4% of the FH patients had TC levels below
5.0 mmo1/1, while only 24% of those patients who suffered
from CHD had similarly controlled TC levels. Almost 20% of
the FH patients had TC levels above 8.0 mmo1/l.
The degree of TC lowering could be determined for patients
who had an initial and a most recent recorded TC level while
under treatment of the participating doctors. For FH patients
their latest TC level was 14.6% lower than their initial level, for
those with CHD the reduction was only 11.3%, while for
patients without CHD it was 5.7%. The levels achieved in these
groups of patients, after treatment, were very much higher than
those recommended by the South African Guidelines.
Participating doctors reported that all the FH patients were
given either a diet or lipid-lowering agents, while 40.8% of the
CHD patients and 28.5% of the non-CHD patients received
such treatment. Only 59.6% of the FH patients had specific
lipid-lowering agents recorded on their data sheets, while this
figure was 17.3% and 7.2% for the CHD and non-CHD patients,
respectively. By far the most commonly prescribed group of
lipid-lowering agents was the HMG-CoA reductase inhibitors,
with the fibrates the next commonest group of agents
prescribed. Very few of the other lipid-lowering agents were
prescribed and only 6.1 % of the FH patients received a
Table n. Profile of South African patients participating in the 1993/4 Cholesterol Monitor survey
Total Men Women
(N = 12 842) (N = 5 754) (N = 7 038)
% % N % N
Patients who had ever had their TC level measured 39.1 5018 49.3 2839 30.6 2156
Of these, patients who had their latest TC level recorded 86.4 875 85.9
Mean TC level of these patients (mrnol/I) 5.8 4336 5.8 2484 5.8 1852
Distribution of patients' most recent recorded TC levels
TC < 5 mrnol/l 28.0 1215 26.4 655 30.2 560
TC ~ 5 < 6.5 mmol/l SO.O 2168 52.0 1293 47.3 875
TC ~ 6.5 < 8 mmol/I 17.9 774 18.0 448 17.6 326
TC ~ 8 mrnol/I 4.1 179 3.6 88 4.9 91
Patients reported to be suffering from CHD' 14.1 1813 18.7 1078 10.4 729
Patients with CHD (N = 1 813) who had ever had their TC measured 67.1 1216 75.2 811 55.0 401
Patients with CHD (N = 1 813) who had recorded TC levels 60.5 1097 68.3 736 49.5 361
Mean TC level of these CHD patients (mmol/l) 6.0 1097 5.9 136 6.0 361
Patients reported to have FH 3.1 396 4.1 234 2-3 161
Patients reported as having a family history of cardiovascular disease 12.8 1640 13.0 749 12.6 886
Patients reported to be obese 32.0 4085 28.2 1620 34.8 2451
Patients reported to be smokers 72.0 9198 64.4 3704 77.5 5453
Patients reported to have hypertension 23.1 2961 24.9 1437 20.5 1516
Patients reported to have diabetes 5.3 681 6.3 360 4.5 316
Patients who had one or more CHD risk fadorst 81.0 10384 76.6 4406 82.3 5933
'Patients who were reported to suffer from IHD, arteriosclerosis. previous myocardial infarction, arrhythmia or cardiac insufficiency.
tCHD risk factors considered were cigarette smoking, hypertension. family history of CHD. diabetes, elevated higlycerides.
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Patients whose TC level was reportedly never measured
Patients who had their most recent TC level recorded
Mean latest TC value recorded for the whole group (mrno1/1)*
Distribution of patients' most recent recorded TC levels'
< 5mmo1/1
~ 5 < 6.5 mmo1/1
~ 6.5 < 8 mmo1/1
~8mmo1/1
Patients who had their initial and latest TC levels recorded
Mean initial TC value (mmo1/1)+
Mean latest TC value recorded (mmo1/1)+
Patients, with latest TC level, who received either a diet or drug treatment
Patients given lifestyle improvement advice
Patients given a specific cholesterol-lowering diet
Patients for whom a specific lipid-lowering agent was recorded
Patients who received a HMG-CoA reductase inhibitor
Patients who received fibrates
Patients who received probucol
Patients who received cholestyramine
Patients who received nicotinic acid
Patients on more than one drug
Mean TC level that doctors realistically expected patients to achieve
Mean TC level that doctors reported to be a satisfactory level to achieve
'Denominator those patients who had a latest known Te level recorded.






















Patients reported Patients without
to have CHD reported CHD
(N =I 066) (N =3556)
% N % N
35.9 597 67.0 7227
89.7 958 84.7 3013
5.8 955 5.6 3013
24.0 229 32.2 970
55.4 529 50.2 1514
18.0 172 14.7 444
2.6 25 2.9 85
37.9 404 23.6 840
7.1 404 7.0 840
6.3 404 6.6 840
40.8 430/958 28.5 859/3 013
30.8 329 19.9 709
25 267 15.0 532
17.3 184 7.2 256
12.5 133 4.8 172
3.4 36 1.7 61
0.8 8 < 0.01 10
<0.01 2 < 0.01 1
<0.01 2 0.0 0
0.4 8 < 0.01 5
5.5 417 5.6 828
5.4 416 5.4 825
combination of two agents. The effect of the different classes of
lipid-lowering agents was assessed in patients for whom
baseline and follow-up TC levels were recorded. Compared
with the initial TC reading, the percentage of patients with a
TC level above 6.5 mmo1/1 at follow-up was reduced by 40.4%
and 37.4% for those who received HMG-CoA reductase
inhibitors and fibrates, respectively.
In addition to the TC levels actually recorded for the
patients, the doctors also recorded much lower TC levels that
they felt would be realistic and/or satisfactory to achieve:
DISCUSSIO
The market research company that collected the data shown
here is of high standing, and used internationally accepted
market research methodology. The two major differences
distinguishing this methodology from that usually followed in
epidemiological surveys are firstly the process and sampling
frames that were used to generate the study population, and
secondly the data on TC levels. Information in this study is
based on those TC levels recorded by the doctors and not
actual serum TC measurements. In epidemiological parlance
this sample would be considered a convenience sample with all
the possible biases that apply to data collected from such study
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populations. This sampling frame is clearly biased towards
participants from urban areas and smaller towns close to cities.
The results will not be generalisable to private practice patients
from deep rural areas. Furthermore, doctors in solo practices
will also be over-represented in the sample compared with
doctors in practices that have more than one partner, as only
one partner per practice was selected. Only doctors from busy
practices were included as one of the selection criteria was that
doctors should see a minimum of 25 patients per day. Finally,
the possibility needs to be considered that this type of survey
attracts participating private practitioners who are enthusiastic
about the management of hyperlipidaemia. As such these
results may give a more optimistic picture of hyperlipidaemia
management than actually prevails in South African private
practices.
Despite the above limitations, these data represent
information on hyperlipidaemia in the largest sample of South
African patients ever reported. It is unlikely that more
representative local data on hyperlipidaemia will be collected
in the foreseeable future; as such the Cholesterol Monitor
provides the best available data on hyperlipidaemia in the
South African population attending private health services.
All published guidelines on the management of
hyperlipidaemia emphasise that persons who have already
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suffered from atherosclerosis-related conditions, such as angina
or a myocardial infarction, should have their lipid levels
controlled in order to prevent further ischaemic events.l'; The
overall impression from these data is that South African
patients who are attending private practitioners and who are
known to be at high risk for CHD are not having their TC
levels measured frequently enough, and when measured, are
not managed effectively. Table II indicates that this seems to be
the case particularly for women, whether they suffered from
CHD or not. Only 50% of the women with CHD had recorded
TC levels, while just less than 70% of men had their levels
recorded. This neglect of appropriate preventive action in
female CHD patients, and those without CHD, has been
recorded in a number of countries and probably reflects the
long-held notion that CHD is less common in women than in
men.'
Low screening rates for hypercholesterolaemia could be due
to various reasons, one being the lack of awareness that
hypercholesterolaemia is a health risk. The conflicting
messages in the media regarding appropriate nutrition and the
importance of hypercholesterolaemia as a health risk may also
play a role. High costs for TC tests and/or drugs are factors
that could influence clinician and patient behaviour.
Data in Table IT further illustrate the high level of CHD risk
reported in the Cholesterol Monitor. The high rate of tobacco
smoking in women is of particular concern. Such high smoking
rates have also been reported in a study by Volmink et al." of a
group of general practices in the Western Cape. This certainly
suggests that smokers attend general practices more frequently
than patients with risk factors such as diabetes and
hypertension. The rates for the latter two conditions reported
in our study are similar to those reported in population
surveys conducted in South African populations.'o.ll The rate of
smoking in South Africa has recently been reported as being
34% (52% in men, 17% in women).l2 Another possibility is that
the private practitioners overestimated smoking rates of their
patients, particularly among women. Similarly, the reported
rate of patients suffering from FH (3.1%) is much higher than
the rate estimated by Steyn et al. (0.28%).13 A community with
such a high CHD risk should certainly have a higher screening
rate for TC than 39% if the impact of this risk on CHD
mortality and morbidity is to be reduced.
Table III shows a poor level of cholesterol control in patients
who either have FH or were already suffering from CHD.
About 75% of CHD patients had TC levels above 5 mmol/I in
excess of the USA's National Cholesterol Education Programme
guidelines, which still carry risk for further CHD events. The
recent Scandinavian Simvastatin Survival Study and some
meta-analyses of earlier studies on secondary prevention have
clearly shown that these patients could benefit substantially by
reducing their TC levels.!'·1S An interesting finding was that the
levels of those patients who had both initial and recent TC
levels recorded had markedly higher TC levels than those for
whom only one such level was recorded. The group of patients
for whom more than one TC level was recorded certainly had
not been treated effectively enough to reach well-controlled TC
levels or those levels that their doctors realistically expected
them to achieve.
Lifestyle and dietary management form the backbone of
hyperlipidaemia management, particularly in patients who
require secondary preventive procedures.1-4 This approach has
not been followed for the CHD patients whose data were
reported in the South African Cholesterol Monitor. Only 30% of
these patients were given lifestyle improvement advice and
only 25% were given a specific cholesterol-lowering diet. Surely
such interventions would be the most cost-effective way to
protect these patients against further atherosclerosis-related
inddents.
Table III reveals that the HMG-CoA reductase inhibitors have
the major portion of the market for cholesterol-lowering agents.
Further analyses made it clear that the most frequently
prescribed drug for hypercholesterolaemia was simvastatin
(Zocor). In December 1995 it was reported in the popular
magazine Die Kat that simvastatin was one of the 10 most
popular prescribed pharmaceutical agents in South Africa. A
more potent HMG-CoA reductase inhibitor, atorvastatin, has
recently been registered by the South African Medicines
Control Council. I' Bezafibrate was the most frequently
prescribed fibrate, probably because a single daily dose of this
slow-releasing fibrate is available on the local market.
Table IV. Comparison of hypercholesterolaemia management in South Africa and five European countries
South Africa France Germany
Cholesterol testing rate (0/0)
Cholesterol testing rate in aID patients (0/0)
Mean pretreatment TC levels of CHD patients (mmol/I)*
Mean TC level of aID patients on treatment"
CHD patients with TC < 5.0 mmol/l (%)
Reduction from baseline' (%)
Reduction required to reach TC < 5.0 mmol/l (%)
'These data, with the exclusion of South Africa, are from Shephenl and Pratt!






























Bezafibrate could, therefore, be expected to have a higher
compliance rate than other fibrates, as these all require multiple
daily dosages.
Table N compares the data recorded in the South African
Cholesterol Monitor with those recorded in five European
countries7 using similar methodology. Cholesterol testing for all
patients studied and for those with CHD was less frequently
reported in South Africa than in France, Germany or Italy, but
more frequently reported than in Sweden Or the UK. Patients
from France had the greatest cholesterol-lowering reported,
followed by Germany and Italy, while South African, Swedish
and UK patients only succeeded in reducing their TC levels by
an average of 12%. It is well documented that the lowering of
CHD rates recorded in America, Australia and ew Zealand
has not been achieved in the UK.17.18 The fact.that South African
TC reduction rates are similar to those reported in the UK,
suggests that CHD mortality may also decline as slowly in the
portion of our community that currently has high CHD
mortality rates. The degree of TC reduction needed to achieve
TC levels below 5.0 mmol/l for all six countries is substantial
(Table N), and approximates the degree of cholesterol lowering
that has occurred in countries that have reduced their CHD
mortality rates significantly.19
Despite all the reservations regarding data from a
convenience sample using market research techniques, the
picture of inadequate hypercholesterolaemia management that
emerged is so marked that there must be grave concern for the
future of CHD mortality in South Africa. There clearly is an
enormous task at hand if patients with hypercholesterolaemia
are to receive appropriate treatment, which has been shown to
reduce cardiovascular disease through mOre effective TC
control programmes in many countries.
To remedy poor management of hypercholesterolaemia will
require extensive intervention. It will be necessary to raise the
awareness of the public and health care providers with regard
to the need and benefits of effective management, induding the
high costs of the relevant pharmaceutical agents. Continuing
medical education and the development of treatment protocols
and appropriate health education material are central to good
cholesterol management. Informative food labelling and the
development of reasonably priced cholesterol-lowering food
products· all play an important role in hypercholesterolaemia
management.
The reduction of hypercholesterolaemia reduces morbidity
and mortality due to CHD in westernised communities. With
the upward sodal mobility of significant sections of the South
African community, hypercholesterolaemia management will
become an ever-increasing health risk in the country. 'Health
services, particularly in the private sector, will have to be
prepared for this.
This study was funded and conducted by the pharmaceutical
company Merck, Sharp & Dohme. The authors wish to
acknowledge their role in providing the researchers with data that
would otherwise not have been available.
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